Sinovac Biotech ( (SVA) ) has released a notification of late filing.
Sinovac Biotech Ltd. has announced a delay in filing its Annual Report on Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the resignation of their independent registered public accounting firm, Grant Thornton, which has led to a reevaluation of previously issued financial statements. The company is actively seeking a new auditor and plans to file the report as soon as the necessary audited financial statements are available. Sinovac has indicated that there might be significant changes in financial results compared to the previous year, but the exact impact remains uncertain. The company is committed to resolving these issues promptly, as stated by Sven H. Borho, Director & Chair of the Audit Committee.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
Learn more about SVA stock on TipRanks’ Stock Analysis page.